Christopher Oezbek

Christopher Oezbek is an accomplished professional with extensive experience in technology management and development across various industries, particularly in MedTech and FinTech. As the Owner and General Manager of Özbek Ventures GmbH since January 2021, Christopher invests in start-ups including Diametos.com and Clous. At Nephrolytix, from January 2021 to August 2024, Christopher served as Chief Technology Officer, successfully launching an In-Vitro Diagnostic product for measuring kidney function in Europe. Prior roles include Head of Engineering Frontend Technologies at DKB, Senior Manager R&D at Stryker Advanced Guidance Technologies, and Chief Technology Officer at Scopis Medical, where Christopher played pivotal roles in product development and team management. With a Ph.D. in Computer Science from Freie Universität Berlin and a Master's from Georgia Institute of Technology, Christopher has a solid academic foundation supporting a distinguished career in technology.